Abstract:Cytochrome P450 3A4 (CYP3A4), a key enzyme, is pivotal in metabolizing approximately half of the drugs used clinically. The genetic polymorphism of the CYP3A4 gene significantly influences individual variations in drug metabolism, potentially leading to severe adverse drug reactions (ADRs). In this study, we conducted a genetic analysis on CYP3A4 gene in 1163 Chinese Han individuals to identify the genetic variations that might affect their drug metabolism capabilities. For this purpose, a multiplex polymerase chain reaction (PCR) amplicon sequencing technique was developed, enabling us to perform the genotyping of CYP3A4 gene efficiently and economically on a large scale. As a result, a total of 14 CYP3A4 allelic variants were identified, comprising six previously reported alleles and eight new nonsynonymous variants that were nominated as new allelic variants *39–*46 by the PharmVar Association. Further, functional assessments of these novel CYP3A4 variants were undertaken by coexpressing them with cytochromes P450 oxidoreductase (CYPOR) in Saccharomyces cerevisiae microsomes. Immunoblot analysis indicated that with the exception of CYP3A4.40 and CYP3A4.45, the protein expression levels of most new variants were similar to that of the wild-type CYP3A4.1 in yeast cells. To evaluate their catalytic activities, midazolam was used as a probe drug. The results showed that variant CYP3A4.45 had almost no catalytic activity, whereas the other variants exhibited significantly reduced drug metabolism abilities. This suggests that the majority of the CYP3A4 variants identified in the Chinese population possess markedly altered capacities for drug metabolism. SIGNIFICANCE STATEMENT In this study, we established a multiplex polymerase chain reaction (PCR) amplicon sequencing method and detected the maximum number of new CYP3A4 variants in a single ethnic population. Additionally, we performed the functional characterizations of these eight novel CYP3A4 allele variants in vitro. This study not only contributes to the understanding of CYP3A4 genetic polymorphism in the Chinese Han population but also holds substantial reference value for their potential clinical applications in personalized medicine.

Effects of ABCB1, ABCC2, UGT2B7 and HNF4α Genetic Polymorphisms on Oxcarbazepine Concentrations and Therapeutic Efficacy in Patients with Epilepsy.

Specific OCT1 and ABCG2 Polymorphisms Are Associated with Lamotrigine Concentrations in Chinese Patients with Epilepsy

Effects of UGT1A9 Genetic Polymorphisms on Monohydroxylated Derivative of Oxcarbazepine Concentrations and Oxcarbazepine Monotherapeutic Efficacy in Chinese Patients with Epilepsy

Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy

ABCB1 c.3435C > T and EPHX1 c.416A > G polymorphisms influence plasma carbamazepine concentration, metabolism, and pharmacoresistance in epileptic patients

Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

Population pharmacokinetics of oxcarbazepine 10-monohydroxy derivative in Chinese adult epileptic patients

The association of ABCB1 gene polymorphism with clinical response to carbamazepine monotherapy in patients with epilepsy

Influence of UGT2B7, UGT1A4 and ABCG2 Polymorphisms on the Pharmacokinetics and Therapeutic Efficacy of Lamotrigine in Patients with Epilepsy

Epigenetic variants of xenobiotic metabolism affect individual differences in antiepileptic drug 3,4-DCPB pharmacokinetic phenotype

Relationship Between Cytochromes P450 2C19 * 2 Genotype and the Concentration of the Active Oxcarbazepine Metabolite in Pediatric Patients with Epilepsy

Influence of UGT2B7 and UGT1A6 polymorphisms on plasma concentration to dose ratio of valproic acid in Chinese epileptic children

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients

The Influence of Cytochrome Oxidase CYP2A6, CYP2B6, and CYP2C9 Polymorphisms on the Plasma Concentrations of Valproic Acid in Epileptic Patients

Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens

Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients

Association of a Polymorphism in MDR1C3435T with Intractable Epilepsy of Children

The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients

Relationship between single nucleotide polymorphisms of CYP3A4 and drug resistant epilepsy in Han Chinese children

Relationship between clinical features of intractable epilepsy in children and the single nucleotide polymorphisms of CYP3A41G